Research Institute Havelhöhe, Berlin, Germany.
Interdisciplinary Oncology and Palliative Care, Hospital Havelhöhe, Berlin, Germany.
Integr Cancer Ther. 2020 Jan-Dec;19:1534735420940384. doi: 10.1177/1534735420940384.
Recent data suggest a beneficial effect of add-on treatment with L (VA) on the survival in cancer patients. The objective of this study was to compare the impact of standard oncological therapy plus add-on VA treatment (S+VA) versus standard oncological therapy alone (S) on the overall survival (OS) of patients with nonmetastasized non-small cell lung carcinoma (NSCLC).
The multicenter real-world data study was conducted using data from the Network Oncology Clinical Registry. The primary end point was OS. OS and impact on hazard in both treatment groups were compared.
A total of 275 patients with stages I to IIIA NSCLC were enrolled (mean age = 67.6 years, 57.2% male patients). No significant difference of OS was observed between both groups. Even though not significant, for a subgroup of unresected patients with stage I NSCLC, adenocarcinoma or squamous cell carcinoma, a medium effect size OS improvement was observed for S+VA compared to S.
Our findings support the importance of surgery as the most effective intervention in nonmetastasized NSCLC patients. Add-on VA therapy shows here no additional effect in resected patients. However, a small subgroup analysis suggests a possible role of add-on VA for nonresected subgroups. Our results complement existing knowledge on the clinical impact of add-on VA therapy in NSCLC patients and may serve as hypothesis-generating data for further examinations in this cohort. Further research could be directed towards the role of combined therapy for nonresected early-stage NSCLC.
最近的数据表明，在癌症患者的治疗中，添加 L（VA）治疗有获益。本研究的目的是比较标准肿瘤治疗加附加 VA 治疗（S+VA）与单纯标准肿瘤治疗（S）对非转移性非小细胞肺癌（NSCLC）患者总生存（OS）的影响。
这项多中心真实世界数据研究使用网络肿瘤临床登记处的数据进行。主要终点是 OS。比较了两组的 OS 和危险度的影响。
共纳入 275 例 I 期至 IIIA 期 NSCLC 患者（平均年龄 67.6 岁，57.2%为男性）。两组之间 OS 无显著差异。尽管没有统计学意义，但对于 I 期 NSCLC、腺癌或鳞状细胞癌的未切除患者亚组，S+VA 组的 OS 改善效果优于 S 组。
我们的研究结果支持手术作为非转移性 NSCLC 患者最有效的干预手段的重要性。附加 VA 治疗在已切除患者中没有显示出额外的效果。然而，一个亚组分析表明，VA 附加治疗对未切除的亚组可能有一定作用。我们的结果补充了现有关于 NSCLC 患者附加 VA 治疗临床影响的知识，并可为该队列的进一步研究提供假设生成数据。进一步的研究可以针对非切除早期 NSCLC 的联合治疗作用进行。
